NKF 2010 Spring Clinical Meeting: Multiple posters on Hematide/peginesatide to be presented

Mar 31 2010

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced multiple posters on Hematide™/peginesatide have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010 in Orlando, Florida. Hematide is an investigational agent for the treatment of anemia in chronic renal failure (also referred to as renal anemia).

Affymax and investigators will present six posters highlighting Phase 2 data on Hematide in renal anemia. Details of the poster presentations at NKF follow:

Wednesday, April 14 2010:

• Long-Term Clinical Experience With Hematide (Schiller, et al.): 6:00PM
• Hemoglobin Decline Following Hematide Dose Interruption (Besarab, et al.): 6:00PM
• Hematide Dose Adjustments in the Maintenance of Hb in Hemodialysis Patients (Whittier, et al.): 6:00PM
• Analysis of Hemoglobin Stability With Hematide in Hemodialysis Patients (Kaplan, et al.): 6:00PM
• EPO and Hematide Requirements Differ in ESA Hyporesponsive HD Patients (Kotanko, et al.): 6:00PM
• Evaluation of the Maintenance of Hb Control in HD Patients Both During and After Hospitalization With Once-Monthly Hematide (Zabaneh, et al.): 6:00PM

*Note: All times are listed in Eastern Time